Cerebrospinal fluid biomarker for Parkinson's disease: An overview
In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often...
Gespeichert in:
| Veröffentlicht in: | Molecular and cellular neuroscience 2019-06, Vol.97, p.60-66 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | |
| container_start_page | 60 |
| container_title | Molecular and cellular neuroscience |
| container_volume | 97 |
| creator | Maass, Fabian Schulz, Isabel Lingor, Paul Mollenhauer, Brit Bähr, Mathias |
| description | In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application. |
| doi_str_mv | 10.1016/j.mcn.2018.12.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2157651157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S104474311830352X</els_id><sourcerecordid>2157651157</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-7292f3c566c7f2bc8d3cd7ed68a026164fb8869f8ae5c9991bc53a4b54c52f0f3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwA1hQNlgS_BE7MUyl4kuqBAPMluOcJZc0LnZTxL_HVQsjy90Nz73S-yB0TnBBMBHXi2Jp-oJiUheEFhjzAzQmWPJcMlodbu-yzKuSkRE6iXGBE0ElO0YjhnnJal6P0d0MAjTBx5XrdZfZbnBt1ji_1OEDQmZ9yF7T6fro-8uYtS6CjnCTTfvMbyBsHHydoiOruwhn-z1B7w_3b7OnfP7y-DybznNTErnOKyqpZYYLYSpLG1O3zLQVtKLWmAoiStvUtZC21sCNlJI0hjNdNrw0nFps2QRd7XJXwX8OENdq6aKBrtM9-CEqSnglOEkzoWSHmtQsBrBqFVyq9K0IVlt1aqGSOrVVpwhVSUz6udjHD80S2r-PX1cJuN0BkEqm4kFF46A30LoAZq1a7_6J_wGrAH54</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157651157</pqid></control><display><type>article</type><title>Cerebrospinal fluid biomarker for Parkinson's disease: An overview</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Maass, Fabian ; Schulz, Isabel ; Lingor, Paul ; Mollenhauer, Brit ; Bähr, Mathias</creator><creatorcontrib>Maass, Fabian ; Schulz, Isabel ; Lingor, Paul ; Mollenhauer, Brit ; Bähr, Mathias</creatorcontrib><description>In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.</description><identifier>ISSN: 1044-7431</identifier><identifier>EISSN: 1095-9327</identifier><identifier>DOI: 10.1016/j.mcn.2018.12.005</identifier><identifier>PMID: 30543858</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>alpha-Synuclein - cerebrospinal fluid ; Amyloid beta-Peptides - cerebrospinal fluid ; Animals ; Biomarker ; Biomarkers - cerebrospinal fluid ; CSF ; Diagnosis, Differential ; Humans ; Inflammation Mediators - cerebrospinal fluid ; Neurofilament Proteins - cerebrospinal fluid ; Parkinson Disease - cerebrospinal fluid ; Parkinson Disease - diagnostic imaging ; Parkinson's disease ; Peptide Fragments - cerebrospinal fluid</subject><ispartof>Molecular and cellular neuroscience, 2019-06, Vol.97, p.60-66</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-7292f3c566c7f2bc8d3cd7ed68a026164fb8869f8ae5c9991bc53a4b54c52f0f3</citedby><cites>FETCH-LOGICAL-c419t-7292f3c566c7f2bc8d3cd7ed68a026164fb8869f8ae5c9991bc53a4b54c52f0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mcn.2018.12.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30543858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maass, Fabian</creatorcontrib><creatorcontrib>Schulz, Isabel</creatorcontrib><creatorcontrib>Lingor, Paul</creatorcontrib><creatorcontrib>Mollenhauer, Brit</creatorcontrib><creatorcontrib>Bähr, Mathias</creatorcontrib><title>Cerebrospinal fluid biomarker for Parkinson's disease: An overview</title><title>Molecular and cellular neuroscience</title><addtitle>Mol Cell Neurosci</addtitle><description>In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.</description><subject>alpha-Synuclein - cerebrospinal fluid</subject><subject>Amyloid beta-Peptides - cerebrospinal fluid</subject><subject>Animals</subject><subject>Biomarker</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>CSF</subject><subject>Diagnosis, Differential</subject><subject>Humans</subject><subject>Inflammation Mediators - cerebrospinal fluid</subject><subject>Neurofilament Proteins - cerebrospinal fluid</subject><subject>Parkinson Disease - cerebrospinal fluid</subject><subject>Parkinson Disease - diagnostic imaging</subject><subject>Parkinson's disease</subject><subject>Peptide Fragments - cerebrospinal fluid</subject><issn>1044-7431</issn><issn>1095-9327</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwA1hQNlgS_BE7MUyl4kuqBAPMluOcJZc0LnZTxL_HVQsjy90Nz73S-yB0TnBBMBHXi2Jp-oJiUheEFhjzAzQmWPJcMlodbu-yzKuSkRE6iXGBE0ElO0YjhnnJal6P0d0MAjTBx5XrdZfZbnBt1ji_1OEDQmZ9yF7T6fro-8uYtS6CjnCTTfvMbyBsHHydoiOruwhn-z1B7w_3b7OnfP7y-DybznNTErnOKyqpZYYLYSpLG1O3zLQVtKLWmAoiStvUtZC21sCNlJI0hjNdNrw0nFps2QRd7XJXwX8OENdq6aKBrtM9-CEqSnglOEkzoWSHmtQsBrBqFVyq9K0IVlt1aqGSOrVVpwhVSUz6udjHD80S2r-PX1cJuN0BkEqm4kFF46A30LoAZq1a7_6J_wGrAH54</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Maass, Fabian</creator><creator>Schulz, Isabel</creator><creator>Lingor, Paul</creator><creator>Mollenhauer, Brit</creator><creator>Bähr, Mathias</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201906</creationdate><title>Cerebrospinal fluid biomarker for Parkinson's disease: An overview</title><author>Maass, Fabian ; Schulz, Isabel ; Lingor, Paul ; Mollenhauer, Brit ; Bähr, Mathias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-7292f3c566c7f2bc8d3cd7ed68a026164fb8869f8ae5c9991bc53a4b54c52f0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>alpha-Synuclein - cerebrospinal fluid</topic><topic>Amyloid beta-Peptides - cerebrospinal fluid</topic><topic>Animals</topic><topic>Biomarker</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>CSF</topic><topic>Diagnosis, Differential</topic><topic>Humans</topic><topic>Inflammation Mediators - cerebrospinal fluid</topic><topic>Neurofilament Proteins - cerebrospinal fluid</topic><topic>Parkinson Disease - cerebrospinal fluid</topic><topic>Parkinson Disease - diagnostic imaging</topic><topic>Parkinson's disease</topic><topic>Peptide Fragments - cerebrospinal fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maass, Fabian</creatorcontrib><creatorcontrib>Schulz, Isabel</creatorcontrib><creatorcontrib>Lingor, Paul</creatorcontrib><creatorcontrib>Mollenhauer, Brit</creatorcontrib><creatorcontrib>Bähr, Mathias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular and cellular neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maass, Fabian</au><au>Schulz, Isabel</au><au>Lingor, Paul</au><au>Mollenhauer, Brit</au><au>Bähr, Mathias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid biomarker for Parkinson's disease: An overview</atitle><jtitle>Molecular and cellular neuroscience</jtitle><addtitle>Mol Cell Neurosci</addtitle><date>2019-06</date><risdate>2019</risdate><volume>97</volume><spage>60</spage><epage>66</epage><pages>60-66</pages><issn>1044-7431</issn><eissn>1095-9327</eissn><abstract>In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30543858</pmid><doi>10.1016/j.mcn.2018.12.005</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-7431 |
| ispartof | Molecular and cellular neuroscience, 2019-06, Vol.97, p.60-66 |
| issn | 1044-7431 1095-9327 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2157651157 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | alpha-Synuclein - cerebrospinal fluid Amyloid beta-Peptides - cerebrospinal fluid Animals Biomarker Biomarkers - cerebrospinal fluid CSF Diagnosis, Differential Humans Inflammation Mediators - cerebrospinal fluid Neurofilament Proteins - cerebrospinal fluid Parkinson Disease - cerebrospinal fluid Parkinson Disease - diagnostic imaging Parkinson's disease Peptide Fragments - cerebrospinal fluid |
| title | Cerebrospinal fluid biomarker for Parkinson's disease: An overview |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A48%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20biomarker%20for%20Parkinson's%20disease:%20An%20overview&rft.jtitle=Molecular%20and%20cellular%20neuroscience&rft.au=Maass,%20Fabian&rft.date=2019-06&rft.volume=97&rft.spage=60&rft.epage=66&rft.pages=60-66&rft.issn=1044-7431&rft.eissn=1095-9327&rft_id=info:doi/10.1016/j.mcn.2018.12.005&rft_dat=%3Cproquest_cross%3E2157651157%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157651157&rft_id=info:pmid/30543858&rft_els_id=S104474311830352X&rfr_iscdi=true |